To identify potential drivers of anti-PD-L1 resistance, we evaluated gene expression by RNA-seq in pre-treatment tumor biopsies from IMmotion150, a randomized phase II trial of previously untreated metastatic renal cell carcinoma (RCC) comparing atezolizumab with or without bevacizumab versus the tyrosine kinase inhibitor sunitinib.11 Here, CD274 is linked to neoplasm.